OSCR

Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes.

Overview

Authors: Tine Deconinck1, Tim Dierckx1, Frederik De Smet2, Jim Baggen1, Dirk Daelemans1
  1. KU Leuven Department of Microbiology, Immunology and Transplantation, Molecular Genetics and Therapeutics in Virology and Oncology Research Group, Rega Institute, Leuven Cancer Institute, 3000 Leuven, Belgium
  2. KU Leuven Department of Imaging and Pathology, Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research, Leuven Cancer Institute, 3000 Leuven, Belgium
Institutions: Rega Institute for Medical Research (Belgium); KU Leuven (Belgium)
Journal: Molecular therapy. Oncology, volume 34, issue 3, article 201263
Dates: received 13 November 2025; accepted 9 June 2026; published online 11 June 2026
Type: Research article · Language: English
License: CC BY-NC-ND
Identifiers: DOI 10.1016/j.omton.2026.201263 · PMID 42441280 · PMCID PMC13334811 · OpenAlex W7164345028
Open access: gold, a free copy (OpenAlex)
Status: code on request (how the code is found and verified)
Categories: human (organism), other condition (population)
Methods: Statistics, Smoothing, state filtering, decompositions, Machine learning, Evoked potentials, Connectivity
Keywords: oncolytic virotherapy, glioblastoma, brain tumor, CNS tumor, personalized medicine
Topic: Virus-based gene therapy research (Genetics, Biochemistry, Genetics and Molecular Biology), according to OpenAlex
Funding: KU Leuven Research Council (3M240253); Research Foundation - Flanders (11M2425N); KU Leuven
Citations: cited by 1 paper (Europe PMC); 84 references in the paper
Research resources: RRID:CVCL_0023, RRID:CVCL_0030, ATCC VR-356) in HeLa Chang liver cells RRID:CVCL_0238, RRID:CVCL_0574, RRID:CVCL_1915, RRID:CVCL_2480, RRID:CVCL_3009, Samtools 1.5 RRID:SCR_002105, RRID:SCR_002798, RRID:SCR_004463, RRID:SCR_006813, RRID:SCR_010974, Adapters were trimmed with cutadapt 1.15 RRID:SCR_011841, FeatureCounts 1.5.3 RRID:SCR_012919, RRID:SCR_014601, RRID:SCR_016341, Using bowtie 2.3.3.1 RRID:SCR_016368, RRID:SCR_016863, CellRanger RRID:SCR_017344, using fgsea82 1.20.0 RRID:SCR_020938

Abstract

The abstract is not reproduced here: the paper's license (CC BY-NC-ND) does not allow it. Read it in the paper, at the publisher or on Europe PMC.

Code

The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.

Data

No dataset and no data link were found in the paper.

Code and data availability statement

The paper has a code and data availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:

  • it says that the data are available on request
  • it says that the code is available on request

Read it in the paper: doi.org/10.1016/j.omton.2026.201263.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 5 authors, 5 keywords, 3 funders, 81 references, 20 RRIDs.

Cite

This paper

Deconinck, T., Dierckx, T., De Smet, F., Baggen, J., & Daelemans, D. (2026). Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes. Molecular therapy. Oncology, 34(3), 201263. https://doi.org/10.1016/j.omton.2026.201263

BibTeX

@article{deconinck2026comparative,
author = {Deconinck, Tine and Dierckx, Tim and De Smet, Frederik and Baggen, Jim and Daelemans, Dirk},
title = {{Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes}},
journal = {Molecular therapy. Oncology},
year = {2026},
month = jun,
volume = {34},
number = {3},
pages = {201263},
publisher = {American Society of Gene \& Cell Therapy},
issn = {2950-3299},
doi = {10.1016/j.omton.2026.201263},
url = {https://doi.org/10.1016/j.omton.2026.201263},
pmid = {42441280},
pmcid = {PMC13334811}
}

RIS

TY - JOUR
AU - Deconinck, Tine
AU - Dierckx, Tim
AU - De Smet, Frederik
AU - Baggen, Jim
AU - Daelemans, Dirk
TI - Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes
T2 - Molecular therapy. Oncology
J2 - Mol Ther Oncol
PY - 2026
DA - 2026/06/11
VL - 34
IS - 3
SP - 201263
SN - 2950-3299
PB - American Society of Gene & Cell Therapy
DO - 10.1016/j.omton.2026.201263
UR - https://doi.org/10.1016/j.omton.2026.201263
LA - en
ER -

CSL-JSON

{
"id": "10.1016/j.omton.2026.201263",
"type": "article-journal",
"title": "Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes",
"container-title": "Molecular therapy. Oncology",
"author": [
{
"family": "Deconinck",
"given": "Tine"
},
{
"family": "Dierckx",
"given": "Tim"
},
{
"family": "De Smet",
"given": "Frederik"
},
{
"family": "Baggen",
"given": "Jim"
},
{
"family": "Daelemans",
"given": "Dirk"
}
],
"container-title-short": "Mol Ther Oncol",
"volume": "34",
"issue": "3",
"page": "201263",
"DOI": "10.1016/j.omton.2026.201263",
"PMID": "42441280",
"PMCID": "PMC13334811",
"ISSN": "2950-3299",
"publisher": "American Society of Gene & Cell Therapy",
"URL": "https://doi.org/10.1016/j.omton.2026.201263",
"language": "en",
"issued": {
"date-parts": [
[
2026,
6,
11
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3389/fimmu.2021.721830
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Journal: Frontiers in immunology
In common: other condition, 8 references
[2] doi:10.1177/11795549261466431
Advances and Future Expectations in Oncolytic Virus Therapy for Glioblastoma: A Systematic Review of Clinical Trials.
Journal: Clinical Medicine Insights. Oncology
In common: other condition, 7 references
[3] doi:10.1016/j.isci.2022.104395 [code]
Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy.
Journal: iScience
In common: other condition, 5 references
[4] doi:10.1002/alz.12760 [code]
CRISPR/Cas9 screen in human iPSC-derived cortical neurons identifies NEK6 as a novel disease modifier of C9orf72 poly(PR) toxicity.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
In common: other condition, author Dirk Daelemans
[5] doi:10.1038/s41598-025-97804-8
Multi-omics analysis reveals key immunogenic signatures induced by oncolytic Zika virus infection of paediatric brain tumour cells.
Journal: Scientific reports
In common: other condition, 3 references
[6] doi:10.1186/s40478-023-01651-5
Translocator protein (18kDA) (TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophages.
Journal: Acta neuropathologica communications
In common: other condition, 3 references
[7] doi:10.3390/ijms26199335
A Novel Serum-Free Triculture Model of Glioblastoma, Astrocytes, and Macrophages.
Journal: International journal of molecular sciences
In common: other condition, 2 references
[8] doi:10.1038/s41591-024-03152-x
Cranioencephalic functional lymphoid units in glioblastoma.
Journal: Nature medicine
In common: other condition, 2 references
[9] doi:10.1016/j.mbs.2025.109531 [code]
CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma.
Journal: Mathematical biosciences
In common: other condition, 2 references
[10] doi:10.1186/s40478-025-01984-3
Curative timed NK cell-based immunochemotherapy aborts brain tumour recurrence driven by mesenchymal glioma stem cells.
Journal: Acta neuropathologica communications
In common: other condition, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.